

## Datasheet: HCA316P

<b>Description:</b>	HUMAN ANTI RANIBIZUMAB:HRP
<b>Specificity:</b>	RANIBIZUMAB
<b>Other names:</b>	Lucentis
<b>Format:</b>	HRP
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD29858_hIgG1
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	■			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

### Product Form

Human IgG1 antibody (lambda light chain) selected from the HuCAL® phage display library and expressed in a human cell line. This antibody is conjugated to horseradish peroxidase (HRP) and supplied as liquid.

### Preparation

Purified IgG prepared by affinity chromatography on Protein A

### Buffer Solution

Phosphate buffered saline

### Preservative Stabilisers

0.01% Thiomersal

### Approx. Protein Concentrations

Antibody concentration 0.1 mg/ml

### Immunogen

Ranibizumab

### Specificity

**Human Anti-Ranibizumab Antibody, clone AbD29858\_hIgG1** is a non-inhibitory, anti-idiotypic antibody in full immunoglobulin format that specifically recognizes the monoclonal antibody drug ranibizumab and ranibizumab when in complex with recombinant human vascular endothelial growth factor A (VEGF-A). It does not recognize free human VEGF-A or bevacizumab. This antibody can be used to measure levels of free ranibizumab and biosimilars in patient samples.

Clone AbD29858\_hIgG1 in full immunoglobulin format can be used to develop a pharmacokinetic

(PK) antigen capture format assay to measure free ranibizumab that has been captured via immobilized VEGF-A.

Ranibizumab (Lucentis) is a humanized Fab fragment antibody (VH3-23/kappa1), originating from the same parental mouse antibody as bevacizumab (Avastin); it has 4 amino acid exchanges in the heavy chain and 1 amino acid exchange in the light chain compared to bevacizumab. Ranibizumab was first approved to treat wet age-related macular degeneration (AMD), a common form of age-related vision loss. It is also approved for the treatment of macular edema following retinal vein occlusion, diabetic macular edema, and diabetic retinopathy. Ranibizumab inhibits angiogenesis by binding to VEGF-A, blocking its interaction with VEGF receptors on the surface of endothelial cells, and thus preventing the subsequent growth of new blood vessels.

[View a summary of all anti-ranibizumab antibodies](#)

---

<b>Affinity</b>	The monovalent intrinsic affinity of AbD29858_hlgG1 was measured as $K_D=18$ nM by real time, label-free molecular interaction analysis on immobilized VEGF/ranibizumab complex.
<b>ELISA</b>	Clone AbD29858_hlgG1 can be used in a direct or indirect ELISA on ranibizumab or as a detection reagent for free ranibizumab captured via immobilized VEGF-A.  Protocol: <a href="#">PK antigen capture ELISA to measure free drug</a>
<b>Storage</b>	Store at Store at -70°C. Storage in frost-free freezers is not recommended. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the antibody. Should this product contain a precipitate we recommend microcentrifugation before use.
<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	Sold under license of U.S. Patents 6753136, 7785859 and 8273688 and corresponding patents. This antibody was developed by Bio-Rad, Zeppelinstr. 4, 82178 Puchheim, Germany. Lucentis is a trademark of Genentech.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10094 available at: 10094: <a href="https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf">https://www.bio-rad-antibodies.com/uploads/MSDS/10094.pdf</a>
<b>Licensed Use</b>	For in vitro research purposes and for commercial applications for the provision of in vitro testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only
<b>Technical Advice</b>	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <a href="#">HuCAL Antibodies Technical Manual</a>

---

## Related Products

### Recommended Negative Controls

[RECOMBINANT HUMAN IgG1 LAMBDA \(HCA049\)](#)

### Recommended Useful Reagents

HISPEC ASSAY DILUENT (BUF049A)  
RECOMBINANT HUMAN VEGF-A (PHP293)

**North & South** Tel: +1 800 265 7376

**America** Fax: +1 919 878 3751

Email: [antibody\\_sales\\_us@bio-rad.com](mailto:antibody_sales_us@bio-rad.com)

**Worldwide**

Tel: +44 (0)1865 852 700

Fax: +44 (0)1865 852 739

Email: [antibody\\_sales\\_uk@bio-rad.com](mailto:antibody_sales_uk@bio-rad.com)

**Europe**

Tel: +49 (0) 89 8090 95 21

Fax: +49 (0) 89 8090 95 50

Email: [antibody\\_sales\\_de@bio-rad.com](mailto:antibody_sales_de@bio-rad.com)

'M337082:181214'

**Printed on 11 Oct 2019**

---

© 2019 Bio-Rad Laboratories Inc | [Legal](#) | [Imprint](#)